Oxaliplatin-based adjuvant chemotherapy was demonstrated to be beneficial for stage III or high-risk stage II colorectal cancer (CRC). Moreover, a recent international collaborative trial suggested 3-months CAPOX as an alternative regimen for low-risk stage III colorectal cancer (CRC) patients. Thus, it is important to clarify the frequency and predictive markers of dose-limiting toxicities (DLTs) developed within the short-course CAPOX cycles.

中文翻译：

---

女性在辅助性 CAPOX 治疗结直肠癌期间容易出现早期剂量限制性毒性

以奥沙利铂为基础的辅助化疗已被证明对 III 期或高危 II 期结直肠癌 (CRC) 有益。此外，最近的一项国际合作试验建议将 3 个月的 CAPOX 作为低风险 III 期结直肠癌 (CRC) 患者的替代方案。因此，澄清在短程 CAPOX 周期内产生的剂量限制性毒性 (DLT) 的频率和预测标志物非常重要。